DiObex Inc.

DiObex Inc. is named for the diseases its founders hope to treat-diabetes, obesity, and syndrome X, a poorly understood precursor to Type II diabetes. The company has in-licensed and is developing two products: DIO-901, a long-acting glucagon to prevent insulin-induced hypoglycemia in Type I diabetics, and DIO-902, a cortisol synthesis inhibitor to treat metabolic disorders such as Type II diabetes and syndrome X.